GlassScriptPhysician profile
Ahmad Agha
NPI 1730520768
$4,145.26
in general payments reported to CMS, 2019-2025
38 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $275 · 2021: $265 · 2022: $578 · 2023: $599 · 2024: $964 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,577.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $620.87 | 2019-2024 | |
| Boston Scientific Corporation | $382.85 | 2019-2025 | General - Structural Heart, Versacross Large Access Solution, Avvigo Guidance System |
| Abiomed | $310.59 | 2019-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $249.28 | 2020-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $236.84 | 2021-2025 | Diamondback Coronary, Esprit, Cardiomems |
| Merck Sharp & Dohme LLC | $230.59 | 2022-2023 | Verquvo |
| Glaxosmithkline, LLC. | $214.66 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Medtronic, INC. | $207.86 | 2022-2025 | Hawkone |
| Pfizer INC. | $204.78 | 2022-2025 | |
| Shockwave Medical, INC | $197.32 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $175.11 | 2019-2023 | Repatha |
| Baxter Healthcare | $154.82 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $128.27 | 2020-2024 | Xarelto |
| Chiesi USA, INC. | $94.03 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $92.82 | 2024 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Agha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.